Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding

Clinical Neuropharmacology

Volumn 23, Issue 1, 2000, Pages 22-27

  Laine, Kari ^b   Anttila, Markku ^a   Huupponen, Risto ^c   Mäki Ikola, Outi ^a   Heinonen, Esa ^a  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NONE

Author keywords

Desmethylselegiline; First pass metabolism; Multiple dose; Pharmacokinetics; Saturable tissue binding; Selegiline

Indexed keywords

AMPHETAMINE DERIVATIVE; DESMETHYLSELEGILINE; METHAMPHETAMINE; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BINDING; DRUG HALF LIFE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AMPHETAMINE; AMPHETAMINES; AREA UNDER CURVE; BINDING SITES; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; MALE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE;

EID: 0033980050     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200001000-00005     Document Type: Article

References (23)

1. Koller WC. Selegiline monotherapy in the treatment of Parkinson's disease. Neurology 1996;47(suppl):S196-9.
2. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
3. Myllylä VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH. Role of selegiline in combination therapy of Parkinson's disease. Neurology 1996;47(suppl):S200-9.
4. Heinonen EH, Anttila M, Karnani H, Lammintausta R. Pharmacokinetics of selegiline after oral dosing [abstract]. Mov Disord 1994; 9(suppl 1):P248.
5. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-55.
6. Heinonen EH, Anttila MI, Lammintausta RAS. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994;56:742-9.
7. Wacher VJ, Wong S, Wong HT, Benet LZ. Contribution of CYP3A to selegiline metabolism in rat and human liver microsomes [abstract]. ISSX Proceedings 1996;10:351.
8. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33:91-102.
9. Scheinin H, Anttila M, Dahl M-L, et al. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Clin Pharmacol Ther 1998;64:402-11.
10. Heinonen EH, Anttila MI, Nyman L et al. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of MAO-B in human subjects. J Clin Pharmacol 1997;37:602-9.
11. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994;56:248-52.
12. Heinonen EH. Selegiline in the treatment of Parkinson's disease: Pharmacokinetic and clinical studies. Academic Dissertation, University of Turku (Finland), 1995.
13. 11C-labeled suicide inactivators and PET. Science 1987;235:481-5.
14. Bench CJ, Price GW, Lammertsma AA et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991;40: 169-73.
15. Barrett JS, Rohatagi S, DeWitt KE, Morales RJ, Disanto AR. The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug Eldepryl (selegiline hydrochloride). Am J Ther 1996;3:298-313.
16. Schultz R, Antonin K-H, Hoffman E, et al. Tyramine kinetics and presser sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989;46:528-36.
17. Sleight AJ, Marsden CA, Martin KF, Palfreyman MG. Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and 1-tryptophan. Br J Pharmacol 1988;93:303-10.
18. Blackwell B. Hypertensive crises due to monoamine-oxidase inhibitors. Lancet 1963;2:849-50.
19. Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 1986;46:1359-65
20. Simpson GM, Frederickson E, Palmer R, Pi E, Sloane RB, White K. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use. Biol Psychiatry 1985;20:680-4.
21. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH. Implications of combined treatment with Madopar and L-deprenyl therapy in Parkinson's disease. Lancet 1977;1:439-43.
22. Lee DH, Mendoza M, Dvorozniak MT, Chung E, van Woert MH, Yahr MD. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. J Neural Transm 1989;1:189-94.
23. Robinson DS, Kurtz NM. Monoamine oxidase inhibiting drugs: Pharmacologic and therapeutic issues. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987:1297-304.